HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RYTELO safely and effectively. See full prescribing information for RYTELO. RYTELO (imetelstat) for injection, for intravenous use. Initial U.S. Approval: 2024 . RYTELO is an oligonucleotide telomerase inhibitor indicated for the
Full prescribing information for Rytelo will be posted here. Efficacy was evaluated in IMerge (NCT ), a randomized (2:1), double
We believe that the placement of RYTELO in the updated MDS NCCN Guidelines reflects the strength of our Phase 3 data and the U.S. Prescribing Information, and that these updates will help to
Rytelo, an oligonucleotide telomerase inhibitor, is indicated for the treatment of low- to intermediate- Rytelo intravenous infusion [prescribing information
RYTELO. Based on the clinical profile of RYTELO, the approved U.S. prescribing information, and now a great set of NCCN Guidelines, we
The FDA approved imetelstat (Rytelo) in June 2024 Rytelo. Prescribing information. Geron Corporation; 2024. Accessed
Entrectinib [package insert]. Genentech USA; August 2024. Accessed Rytelo. Prescribing information. Geron Corporation; 2024
Prescribing Information, and that these updates will help to increase Geron announces updated NCCN Guidelines recommending RYTELO
Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron s belief that placement of RYTELO in the updated MDS NCCN Guidelines reflects the strength of its Phase 3 data and the U.S. Prescribing Information, and that these updates will help to increase awareness and uptake of RYTELO as a compelling
Comments